These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 6441306

  • 1. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor.
    Cerletti C, Rajtar G, Bertelé V, de Gaetano G.
    Thromb Haemost; 1984 Oct 31; 52(2):215. PubMed ID: 6441306
    [No Abstract] [Full Text] [Related]

  • 2. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J.
    J Clin Invest; 1987 Nov 31; 80(5):1435-45. PubMed ID: 2960694
    [Abstract] [Full Text] [Related]

  • 3. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
    Lancet; 1982 Nov 20; 2(8308):1156-7. PubMed ID: 6128469
    [No Abstract] [Full Text] [Related]

  • 4. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
    Schumacher WA, Lucchesi BR.
    J Pharmacol Exp Ther; 1983 Dec 20; 227(3):790-6. PubMed ID: 6418881
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
    Hiraku S, Wakitani K, Katsube N, Kawasaki A, Tsuboshima M, Naito J, Ujiie A, Komatsu H, Iizuka K.
    Adv Prostaglandin Thromboxane Leukot Res; 1983 Dec 20; 11():241-4. PubMed ID: 6221530
    [No Abstract] [Full Text] [Related]

  • 6. Platelet aggregation in whole blood: the role of thromboxane A2 and adenosine diphosphate.
    Carter AJ, Heptinstall S.
    Thromb Haemost; 1985 Oct 30; 54(3):612-6. PubMed ID: 3937261
    [Abstract] [Full Text] [Related]

  • 7. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
    Dale J, Thaulow E, Myhre E, Parry J.
    Thromb Haemost; 1983 Oct 31; 50(3):703-6. PubMed ID: 6689091
    [Abstract] [Full Text] [Related]

  • 8. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma".
    Bertelé V, Falanga A, Tomasiak M, Dejana E, Cerletti C, de Gaetano G.
    Science; 1983 Apr 29; 220(4596):517-9. PubMed ID: 6682245
    [Abstract] [Full Text] [Related]

  • 9. Effect of SQ 80,338 (1-(3-phenyl-2-propenyl)-1H-imidazole) on thromboxane synthetase activity and arachidonic acid-induced platelet aggregation and bronchoconstriction.
    Harris DN, Greenberg R, Phillips MB, Osman GH, Antonaccio MJ.
    Adv Prostaglandin Thromboxane Res; 1980 Apr 29; 6():437-41. PubMed ID: 7189949
    [No Abstract] [Full Text] [Related]

  • 10. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.
    Randall MJ, Parry MJ, Hawkeswood E, Cross PE, Dickinson RP.
    Thromb Res; 1980 Apr 29; 23(1-2):145-62. PubMed ID: 6795753
    [No Abstract] [Full Text] [Related]

  • 11. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
    Lecompte T, Joussemet M, Hainaut J.
    Thromb Res; 1984 Jul 01; 35(1):91-7. PubMed ID: 6089368
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin.
    Bertelé V, Falanga A, Roncaglioni MC, Cerletti C, de Gaetano G.
    Thromb Haemost; 1982 Jun 28; 47(3):294. PubMed ID: 7051411
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the effects of selective inhibition of thromboxane synthase with those of inhibition of the cyclooxygenase enzyme in man.
    Oates JA, Brash A, Fitzgerald G.
    Trans Am Clin Climatol Assoc; 1984 Jun 28; 95():157-62. PubMed ID: 6433527
    [No Abstract] [Full Text] [Related]

  • 16. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
    Sills T, Heptinstall S.
    Thromb Haemost; 1986 Jun 30; 55(3):305-8. PubMed ID: 3018954
    [Abstract] [Full Text] [Related]

  • 17. Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy.
    Horn EH, Hardy E, Cooper J, Heptinstall S, Rubin PC.
    Thromb Haemost; 1996 Feb 30; 75(2):346-51. PubMed ID: 8815588
    [Abstract] [Full Text] [Related]

  • 18. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR.
    Adv Prostaglandin Thromboxane Res; 1980 Feb 30; 6():417-25. PubMed ID: 6247892
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
    Kayama N, Sakaguchi K, Kaneko S, Kubota T, Fukuzawa T, Kawamura S, Yoshimoto T, Yamamoto S.
    Prostaglandins; 1981 Apr 30; 21(4):543-54. PubMed ID: 7196056
    [Abstract] [Full Text] [Related]

  • 20. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
    Fitzpatrick FA, Gorman RR.
    Biochim Biophys Acta; 1978 Mar 01; 539(2):162-72. PubMed ID: 629996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.